Ironomycin

Ironomycin is a derivative of Salinomycin (HY-15597) . Ironomycin exhibits selective inhibitory activity against mantle cell lymphoma (MCL) cells. Ironomycin blocks the cell cycle and induces apoptosis and ferroptosis. Ironomycin induces double-strand DNA breaks and activates the unfolded protein response (UPR), particularly the IRE1α signaling pathway accumulation. The combination of Ironomycin with Ibrutinib (HY-10997) shows a synergistic effect. Ironomycin can be used for the study of MCL.

Product Specifications

CAS Number

[1884647-72-6]

UNSPSC

12352005

Target

Apoptosis; Caspase; CDK; DNA/RNA Synthesis; Drug Derivative; Ferroptosis; IRE1

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Others

Field of Research

Cancer

Smiles

C#CCN[C@H]1[C@@]2(O[C@@](CC2)([C@]3([H])O[C@H]([C@](O)(CC3)CC)C)C)O[C@]4(C=C1)O[C@]([C@H](C[C@H]4C)C)([H])[C@@H](CC)C([C@@H](C)[C@@H](O)[C@@H]([C@]5([H])O[C@@](CC[C@@H]5C)([H])[C@@H](CC)C(O)=O)C)=O

Molecular Formula

C45H73NO10

Molecular Weight

788.06

References & Citations

[1]Antoszczak M, et al. Rapid Access to Ironomycin Derivatives by Click Chemistry. ACS Org Inorg Au. 2022 Jun 1;2 (3) :222-228.|[2]Ovejero S, et al. Ironomycin induces mantle cell lymphoma cell death by targeting iron metabolism addiction. Theranostics. 2025 Feb 3;15 (7) :2834-2851.